Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer
Chemical Biology & Drug Design · 2026-05 · 107 (5)
DOI: 10.1111/cbdd.70321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 26.05.2026. Verfasst von Ivana Kuzminac und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Sciences, Department of Chemistry, Biochemistry and Environmental Protection, University of Novi Sad, Novi Sad, Serbia. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents. Die Arbeit nennt 67 Literaturangaben. Gefördert von: the Ministry of Science, Technological Development and Innovation of the Republic of Serbia, the bilateral cooperation between the Republic of Austria and the Republic of Serbia.
Abstract (Originalsprache)
Breast cancer remains the most prevalent cancer among women, driving the continuous search for novel anticancer agents. In this study, a series of 10‐alkoxy steroids containing a 1,4‐dien‐3‐one moiety was synthesized via a one‐step dearomatization of the A‐ring of estradiol and an estrane derivative with a D‐homo lactone moiety. All compounds exhibited favorable in silico ADMET properties, while five derivatives showed significant cytotoxic activity in vitro. The strongest effects against the estrogen‐positive breast cancer cell line MCF‐7 were observed for two 10β‐methoxy, one 10β‐butoxy, and two 10β‐propargyloxy derivatives. The activity of the 10β‐butoxy‐17β‐hydroxy and 10β‐propargyloxy‐17β‐hydroxy steroids correlates with strong binding affinity toward estrogen receptor α and inhibition of AKR1C3 and AKR1C4 enzymatic activity. Additionally, the propargyloxy derivative showed substrate‐like binding to human recombinant aromatase. Molecular docking results are in qualitative agreement with these findings, predicting binding modes similar to known ligands and possible hydrophobic interactions between the C‐10 alkoxy groups and the active sites of target proteins, particularly the heme group of aromatase. These results highlight novel estrane derivatives as promising candidates for estrogen‐positive breast cancer therapy through combined effects involving AKR1C3 inhibition and interaction with aromatase and estrogen receptor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Sciences, Department of Chemistry, Biochemistry and Environmental Protection, University of Novi Sad, Novi Sad, Serbia.
- Faculty of Life Sciences, Department of Pharmaceutical Sciences, Clinical Pharmacy Group, University of Vienna, Vienna, Austria.
- Faculty of Sciences, Department of Biology and Ecology, University of Novi Sad, Novi Sad, Serbia.
ORCID-Profile: Ivana Kuzminac, Sofija Bekić, Anđelka Ćelić
Förderung
- the Ministry of Science, Technological Development and Innovation of the Republic of Serbia
- the bilateral cooperation between the Republic of Austria and the Republic of Serbia
Zitieren
APA
Kuzminac, I., Bekić, S., Stevanović, M., Scholda, J., Kopp, F., Petri, E., Ćelić, A., & Sakač, M. (2026). Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer. Chemical Biology & Drug Design, 107(5). https://doi.org/10.1111/cbdd.70321
Vancouver
Kuzminac I, Bekić S, Stevanović M, Scholda J, Kopp F, Petri E, et al. Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer. Chemical Biology & Drug Design. 2026;107(5). doi:10.1111/cbdd.70321
BibTeX
@article{Kuzminac2026,
author = {Kuzminac, Ivana and Bekić, Sofija and Stevanović, Milica and Scholda, Julia and Kopp, Florian and Petri, Edward and Ćelić, Anđelka and Sakač, Marija},
title = {Novel 10‐Alkoxy 1,4‐Dien‐3‐One Estranes as Multitarget Anticancer Agents Against Estrogen‐Positive Breast Cancer},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {5},
doi = {10.1111/cbdd.70321}
}
EUVIMED